Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOXO-338 in Advanced Hematologic Malignancies
NCT05024045Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of LOXO-338 in chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), non-Hodgkin lymphoma (NHL) and 5 more (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 28 days, Response Rate at 2 years and 1 more. Started Sep 2021; status: completed.
02
Drugs
LOXO-338
03
Conditions
chronic lymphocytic leukemia (CLL)marginal zone lymphoma (MZL)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)B-cell lymphoma (BCL)
Beyond the preview
Go deeper on NCT05024045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024045.